David E. Lazar - 24 Nov 2025 Form 4 Insider Report for KALA BIO, Inc. (KALA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: KALA
Reported as of: 24 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Nov 2025, 15:03:05 UTC
Prior SEC filing: 02 Dec 2025
Next SEC filing: 22 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ David E. Lazar

Key filing fact

David E. Lazar filed Form 4 for KALA BIO, Inc. (KALA) on 26 Nov 2025.

Key facts

This page summarizes David E. Lazar's Form 4 filing for KALA BIO, Inc. (KALA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Nov 2025, 15:03.

Change

Previous filing in this sequence was filed on 02 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932843 Primary reporting owner

Lazar David E.

Relationship: Chief Executive Officer, Director
Address: 44, TOWER 100, THE TOWERS, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA
Signature: /s/ David E. Lazar
Signature date: 26 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KALA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 0
Date: 24 Nov 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALA transaction Derivative

Series AA Convertible Preferred Stock

Award

Transaction value
Shares: +900,000
Change %
Price
Shares after: 900,000
Date: 24 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 49,500,000
Exercise price
Footnotes: F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

No shares of common stock are beneficially owned.

Footnote F2

On November 24, 2025, David E. Lazar (the "Reporting Person") and KALA BIO, Inc. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired an aggregate of 900,000 shares of the Company's Series AA Convertible Non-Redeemable Preferred Stock (the "Series AA Preferred Stock") at a price of $2.00 per share, for a total purchase price of $1,800,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing, an aggregate of 2,100,000 shares of the Company's Series AAA Convertible Non-Redeemable Preferred Stock (the "Series AAA Preferred Stock", and together with the Series AA Preferred Stock, the "Preferred Stock") at a price of $2.00 per share, for an additional purchase price of $4,200,000.

Footnote F3

Each share of Series AA Preferred Stock will be convertible into 55 shares of the Company's common stock at any time, subject to certain ownership limitations. Each share of Series AAA Preferred Stock will be convertible into 420 shares of the Company's common stock at any time, subject to certain ownership limitations. No shares of Preferred Stock will be convertible until the Company's stockholders approve a) an increase in the Company's authorized capital to enable the Company to issue all of the shares of common stock that are issuable upon the conversion of the Preferred Stock and b) the conversion of the Preferred Stock into shares of common stock in accordance with the listing rules of The Nasdaq Stock Market, LLC (the "Stockholder Approval").

Footnote F4

Following receipt by the Company of the Stockholder Approval, the shares of Series AA Preferred Stock will be convertible at the option of the Reporting Person for no additional consideration.

Footnote F5

The Series AA Preferred Stock is perpetual and therefore has no expiration date.